Effect of Propranolol Combined with Amiodarone on Malignant Arrhythmia

doi:10.13438/j.cnki.jdzk.2021.05.011

Abstract

Abstract: To investigate the effects of propranolol combined with amiodarone on inflammatory factors and QT interval dispersion in patients with malignant arrhythmia. 92 patients with malignant arrhythmia treated in our hospital from February 2018 to June 2020 were randomly divided into two groups with 46 cases in each group. The control group was given amiodarone hydrochloride tablets on the basis of routine treatment, and the observation group was given propranolol hydrochloride tablets on the basis of the control group. The clinical efficacy, inflammatory factors, QT interval dispersion and adverse reactions were compared between the two groups. The results showed that the total effective rate in the observation group was 93.48%, which was higher than 78.26% in the control group (P<0.05). Tumor necrosis factor after treatment α， Interleukin-6, C-reactive protein and QT interval dispersion were lower than those before treatment, but more in the observation group (P<0.05). There were 3 cases of adverse reactions in the control group, which had no significant difference compared with 4 cases in the observation group (P>0.05). It shows that propranolol combined with amiodarone can significantly enhance the clinical efficacy, alleviate inflammatory reaction, reduce QT interval dispersion and have higher safety than amiodarone alone.

Key words: propranolol, amiodarone, malignant arrhythmia, inflammatory factors, QT interval dispersion

BAI Song, ZHAO Dongxian, XU Shanshan, LI Juan, SU Xiaowei, LIU Yan. Effect of Propranolol Combined with Amiodarone on Malignant Arrhythmia[J]. Journal of Jishou University(Natural Sciences Edition), 2021, 42(5): 61-64.

References

[1] 史云桃,蒋廷波.急性ST段抬高型心肌梗死患者恶性室性心律失常的危险因素研究[J].安徽医药,2018,22(11):2134-2137.
[2] JONES J P, RAMCHARAN T, CHAUDHARI M, et al. Ventricular Fibromas in Children, Arrhythmia Risk, and Outcomes: A Multicenter Study[J]. Heart Rhythm, 2018, 15(10): 1507-1512.
[3] 卢小伟.QT离散度、T波峰末间期及血清结缔组织生长因子水平对冠心病恶性心律失常的诊断价值分析[J].实用心脑肺血管病杂志,2017,25(11):59-62.
[4] 徐燕燕,潘泽意,周国勇.胺碘酮联合美托洛尔治疗潜在恶性心律失常的效果观察[J].中国医药,2016,11(11):1589-1592.
[5] NIREI K, NAKAMURA H, MATSUOKA S, et al. Ventricular Tachycardia as a Complication of Ledipasvir and Sofosbuvir Treatment for HCV Infection[J]. Internal Med, 2017, 56(7): 787-790.
[6] 葛均波,徐永健.内科学 [M].8版.北京:人民卫生出版社,2013:102-105.
[7] KELLE A M, BOS J M, ETHERIDGE S P, et al. Cardiac Transplantation in Children and Adolescents with Long QT Syndrome[J]. Heart Rhythm, 2017, 14(8): 1182-1188.
[8] HEBBES C, THOMPSON J P. Drugs Acting on the Heart: Antiarrhythmics[J]. Anaesth Intens Care, 2018, 19(7): 370-374.
[9] NAGHI J J, SIEGEL R J. Medical Management of Hypertrophic Cardiomyopathy[J]. Rev Cardiovasc Med, 2019, 11(4): 202-217.
[10] AN Zhe, YANG Guang, LIU Xuanxuan, et al. New Progress in Understanding the Cellular Mechanisms of Anti-Arrhythmic Drugs[J]. Open Life Sci, 2018, 13(1): 335-339.
[11] BONNY A, NGANTCHA M, SCHOLTZ W, et al. Cardiac Arrhythmias in Africa: Epidemiology, Management Challenges, and Perspectives[J]. Journal of the American College of Cardiology, 2019, 73(1): 100-109.
[12] 王成钢,王春梅,艾辉,等.高敏C-反应蛋白对急性ST段抬高型心肌梗死早期恶性心律失常的预测价值[J].心肺血管病杂志,2019,38(6):589-592.
[13] BULENT G, GIUSEPPE B, GHEORGE-ANDREI D, et al. European Heart Rhythm Association (EHRA) Position Paper on Arrhythmia Management and Device Therapies in Endocrine Disorders, Endorsed by Asia Pacific Heart Rhythm Society (APHRS) and Latin American Heart Rhythm Society (LAHRS)[J]. EP Europace, 2018, 20(6): 895-896.